NCT00505089终止1 期
An Exploratory, Open Label Pharmacokinetic - Pharmacodynamic Study to Compare Subcutaneous Versus Intravenous Administration of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Novartis
- 入组人数
- 11
- 试验地点
- 4
- 主要终点
- - Pharmacokinetic/total IL-1beta pharmacodynamic relationship in joint fluids of patients with rheumatoid arthritis treated with different doses of ACZ885 - Impact of the subcutaneous versus intravenous administration
研究概览
简要总结
This study will investigate the pharmacokinetic (PK) / total IL-1beta pharmacodynamic (PD) relationship in joint fluids of patients with rheumatoid arthritis (RA) treated with different doses of ACZ885 and to evaluate the impact of the subcutaneous (s.c.) versus intravenous (i.v.) route of administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients aged 18 - 75 years (inclusive).
- •Body weight must be between 50 and 100 kg (inclusive).
- •Post-menopausal or surgically sterile female patients. Women of child-bearing potential if already on a stable dose of methotrexate and are practicing effective contraception for at least 3 months prior to screening, have a negative pregnancy test at screening and baseline, and are willing to use 2 forms of contraception including at least 1 barrier method during the study and for at least 2 months following the completion/discontinuation of the study. Male patients must be willing to use an effective contraception method during the study and at least for 2 months following the completion/discontinuation of the study.
- •Diagnosis of Rheumatoid Arthritis, classified by ARA (American Rheumatism Association) 1987 revised criteria (Appendix 2). Disease duration of at least 6 months prior to randomization is essential.
- •Functional status class I, II or III classified according to the ACR (American College of Rheumatology) 1991 revised criteria (Appendix 3).
- •Active disease at screening and baseline (Day 1 predose) evaluation (same evaluator): ≥ 6 tender and ≥ 6 swollen joints of 28 examined (including any effused joint) and either a) Westergren erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour, or b) C-reactive protein (CRP) ≥ 1.0 mg/dL.
- •Prior treatment with 1-3 disease-modifying anti-rheumatic drugs (DMARDs) - Patients should have failed at least 1 DMARD but should not be deemed "refractory to all therapies". Patients should be on a current treatment with methotrexate ≤ 25 mg/week and with the current dose stable for at least 3 months. All patients will take folic acid 1 mg daily, or 5 mg weekly post MTX dose, to minimize toxicity, according to local guidelines. In addition to methotrexate, patients may be on either a stable dose of non-steroidal anti-inflammatory drugs (NSAIDs) and/or a stable dose of oral corticosteroids (prednisone or equivalent ≤ 10 mg daily) for at least 4 weeks prior to randomization. Patients who failed any DMARDs will be allowed.
- •Negative purified protein derivative (PPD) tuberculin skin test reaction (PPD 5 tuberculin units or as according to local standard practice).
- •Patients with a total white cell count and platelet count clinically acceptable for patients with RA; hemoglobin must be ≥ 10 g/dL and hematocrit ≥ 30% at screening and baseline.
排除标准
- •Previous treatment with anti-TNF-α or anti IL-1 therapy (or other biological therapy), immunosuppressive agents such as cyclosporine, mycophenolate or tacrolimus. The following washout period will be required for such patients to be eligible to participate in the trial.
- •2 months washout prior to screening for etanercept or adalimumab
- •3 months washout prior to screening for infliximab
- •3 months washout prior to screening for rituximab
- •1 month washout prior to screening for cyclosporine, mycophenolate and tacrolimus.
- •If patient has been discontinued from other DMARDs for lack of efficacy or toxicity, the patient should be at least 1 month off the agent and the effects of that agent should have dissipated according to the recognized duration of effect (e.g., sulfasalazine, hydroxychloroquine), or standard washout procedure (cholestyramine for leflunomide). Importantly, discontinuation should not be undertaken only for the purposes of participation in this study.
- •Patients who have received intra-articular or systemic corticosteroid injections having been required for treatment of acute RA flare (not being part of a regular therapeutic regimen) within four weeks prior to randomization.
- •Presence of or history of Major chronic inflammatory autoimmune diseases like psoriasis, psoriatic arthritis, spondyloarthropathy, inflammatory bowel disease or systemic lupus erythematosus.
- •Renal trauma, glomerulonephritis or patient with one kidney. Patients with congestive heart failure (New York Heart Association class > III), QT prolongation syndrome or poorly controlled diabetes mellitus. Patients with a history of QTc prolongation will be excluded. A positive HIV test result, Hepatitis B surface antigen or Hepatitis C test result. Significant illness within 2 weeks prior to dosing or any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study. Hypersensitivity to any biological agents, serious allergic reaction, collagen disease, neurological disease (including demyelinating disease). Any joint surgery in past 8 weeks or planned surgery within next 5 months. Cancer (other than basal cell cancer or adequately treated carcinoma-in-situ of the cervix). Drug or alcohol abuse within the 12 months prior to dosing or evidence of such indicated by the laboratory assays conducted during the screening or baseline evaluations. Underlying metabolic, endocrine, hematologic, pulmonary, cardiac, blood, renal, hepatic, infectious, psychiatric or gastrointestinal conditions which places the patient at unacceptable risk for participation in a study of an immunomodulatory therapy.
- •Treatment with an investigational agent within 12 weeks prior to enrollment or longer if required by local regulation.
- •Pregnant or breastfeeding women.
- •Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
1
Experimental
ACZ885 10mg/kg subcutaneous
干预措施: ACZ885 (Drug)
2
Experimental
ACZ885 5mg/kg intravenous
干预措施: ACZ885 (Drug)
3
Experimental
ACZ885 2mg/kg subcutaneous
干预措施: ACZ885 (Drug)
4
Experimental
ACZ885 1mg/kg intravenous
干预措施: ACZ885 (Drug)
结局指标
主要结局
- Pharmacokinetic/total IL-1beta pharmacodynamic relationship in joint fluids of patients with rheumatoid arthritis treated with different doses of ACZ885 - Impact of the subcutaneous versus intravenous administration
时间窗: End of study
次要结局
- - PK/PD of ACZ885 in patient serum and to evaluate impact of s.c. versus i.v. administration - Efficacy via response to treatment (ACR 20% improvement [ACR 20],50,70 & 90)(Days 8,15,29,43 and study completion)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Study of BIIB091 Formulations in Healthy ParticipantsHealthy VolunteersNCT04564612Biogen59
已完成
1 期
Assessment of the Pharmacodynamic and Pharmacokinetic Interaction of Remimazolam and RemifentanilAnesthesiaNCT04670471Paion UK Ltd.28
已完成
1 期
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer SubjectsHealthyNCT01416207Biogen24
已完成
不适用
Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial HypertensionNCT02318186Jeffrey A. Feinstein51
已完成
1 期
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With MigraineMigraineNCT04179474Allergan40